You are here

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
733 Real world data of niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group
  1. Lucia Musacchio1,
  2. Eleonora Palluzzi2,
  3. Marilena Di Napoli3,
  4. Rossella Lauria4,
  5. Gabriella Ferrandina5,
  6. Roberto Angioli6,
  7. Alice Bergamini7,
  8. Giacomo Corrado2,
  9. Giorgia Perniola8,
  10. Chiara Cassani9,
  11. Antonella Savarese10,
  12. Stefania Gori11,
  13. Carmine De Angelis4,
  14. Diana Giannarelli12,
  15. Saverio Cinieri13,
  16. Francesco Raspagliesi14,
  17. Sandro Pignata15 and
  18. Domenica Lorusso12
  1. 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
  2. 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  3. 3Istituto Nazionale Tumori Fondazione G Pascale IRCCS, Napoli, Italy
  4. 4Università Federico II, Napoli, Italy
  5. 5Department of Women’s and Children’s Health, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
  6. 6Campus Biomedico Roma, Rome, Italy
  7. 7IRCCS San Raffaele Hospital, Milan, Italy
  8. 8Sapienza University of Rome, Roma, Italy
  9. 9Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
  10. 10Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy
  11. 11IRCCS Ospedale Sacro Cuore Don Calabria, Verona, Italy
  12. 12Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  13. 13Presidio Ospedaliero Sant Antonio Perrino, Brindisi, Italy
  14. 14Fondazione IRCCS Istituto Nazionale dei Tumori, Gynecological Oncology Unit, Milan, Italy
  15. 15Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy

Abstract

Introduction/Background PARP (poly adenosine diphosphate [ADP]-ribose polymerase) inhibitors are approved as maintenance therapy in platinum sensitive ovarian cancer (OC), in first line and in the recurrent setting, regardless of BRCA mutational status. Real-world data after the introduction of these agents are needed to evaluate whether the benefit observed in phase III randomized clinical trials can be translated into clinical practice. The aim of our study was to provide real-life data on efficacy and safety of niraparib administered as maintenance in platinum sensitive relapsed OC patients (PSROC).

Methodology This observational study included relapsed OC patients that received niraparib as maintenance, at the time of platinum sensitive recurrence within the Italian expanded-access program. Objectives of the study was to describe efficacy of niraparib in a real-world setting in terms of PFS and OS in the overall population and in BRCA mutated and BRCA wild type cohort of patients, as well safety, describing incidence of adverse events (AEs).

Results Among 304 eligible patients, 260 (85%) had BRCA wild-type tumor and 36 (11.9%) were BRCA mutated. Median PFS was 9.1 months (95% CI: 6.9 – 11.2) and 10.3 months (95% CI: 7.0 – 13.5) in the BRCAwt and BRCAmut cohorts, respectively. Furthermore, median OS was 41.7 months (95% CI: 31.6 – 41.9) and 34.6 months (95% CI: N.E.) in the BRCAwt and BRCAmut cohorts, respectively. Most frequently reported Grade 3 or 4 hematologic events were thrombocytopenia (33.1%), anemia (25.0%), and neutropenia (12.5%). Other grade 3–4 non hematologic events were nausea (5.9%), skin toxicity (1.2%) and fatigue (1.2%). There were no myelodysplastic syndrome or acute myeloid leukemia reported. Most of the hematologic laboratory abnormalities occurred within the first five treatment cycles.

Conclusion Data from this large real-life dataset suggested that maintenance with niraparib in the real-life setting of platinum sensitive OC recurrence is effective and well tolerated.

Disclosures The authors have nothing to declare.

https://doi.org/10.1136/ijgc-2024-ESGO.703

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.